1-20 of 31
Cyril H. Benes
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 393: Predictive biomarker evaluation and molecular differentiation for imipridones ONC201 and ONC206

Sara Morrow, Kirti Nath, Yiqun Zhang, Mathew J. Garnett, Ultan McDermott, Cyril H. Benes, Joel Basken, Wafik S. El-Deiry, Joshua E. Allen, Varun V. Prabhu
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 393.
https://doi.org/10.1158/1538-7445.AM2021-393
Published: 01 July 2021
View articletitled, Abstract 393: Predictive biomarker evaluation and molecular differentiation for imipridones ONC201 and ONC206
Journal Articles

Abstract PO-024: Catastrophic ATP loss underlines a metabolic combination therapy tailored for MYCN-amplified neuroblastoma

Krista M. Powell, Timonthy L. Lochmann, Konstantinos V. Floros, Marissa L. Calbert, Richard Kurupi, Giovanna T. Stein, Joseph McClanaghan, Ellen Murchie, Regina K. Egan, Patricia Greninger, Mikhail Dozmorov, Sivapriya Ramamoorthy, Madhavi Puchalapalli, Bin Hu, Lisa Shock, Jennifer Koblisnski, John Glod, Sosipatros A. Boikos, Cyril H. Benes, Anthony C. Faber
Journal: Cancer Research
Cancer Res (2020) 80 (23_Supplement): PO-024.
https://doi.org/10.1158/1538-7445.EPIMETAB20-PO-024
Published: 02 December 2020
View articletitled, Abstract PO-024: Catastrophic ATP loss underlines a metabolic combination therapy tailored for MYCN-amplified neuroblastoma
Journal Articles

Abstract 5688: IND-enabling characterization of ONC206 as the next bitopic antagonist for oncology

Varun Vijay Prabhu, Sara Morrow, Caroline A. Cuoco, Abed R. Kawakibi, Jinkyu Jung, Neel Madhukar, Matthew J. Garnett, Ultan McDermott, Cyril H. Benes, Robert Wechsler-Reya, Lakshmi Anantharaman, Neil Charter, Joseph B. Rucker, Benjamin J. Doranz, Joel Basken, Olivier Elemento, R. Benjamin Free, David R. Sibley, Martin Stogniew, Wolfgang Oster, Mark R. Gilbert, Sharon DeMorrow
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5688.
https://doi.org/10.1158/1538-7445.AM2020-5688
Published: 15 August 2020
View articletitled, Abstract 5688: IND-enabling characterization of ONC206 as the next bitopic antagonist for oncology
Journal Articles

Abstract 1903: PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Ká inhibitors in breast cancer

Carlotta Costa, Ye Wang, Amy Ly, Yasuyuki Hosono, Ellen Murchie, Charlotte S. Walmsley, Tiffany Huynh, Christopher Healy, Rachel Peterson, Shogo Yanase, Charles T. Jakubik, Laura E. Henderson, Leah J. Damon, Daria Timonina, Ioannis Sanidas, Christopher J. Pinto, Mari Mino-Kenudson, James Stone, Nicholas J. Dyson, Leif W. Ellisen, Aditya Bardia, Hiromichi Ebi, Cyril H. Benes, Jeffrey A. Engelman, Dejan Juric
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1903.
https://doi.org/10.1158/1538-7445.AM2020-1903
Published: 15 August 2020
View articletitled, Abstract 1903: PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Ká inhibitors in breast cancer
Journal Articles

Abstract P1-19-28: Genomic screening reveals UBA1 as a potent and druggable target in diverse models of triple negative breast cancer

Sheeba Jacob, Tia H. Turner, Ann K. Yu, Colin M. Coon, Mohammad A. Alzubi, Charles T. Jakubik, Ynes Bouck, Mikhail G. Dozmorov, Sosipatros A. Boikos, Jennifer Koblinski, Joshua C. Harrell, Cyril H. Benes, Carlotta Costa, Anthony C. Faber
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P1-19-28.
https://doi.org/10.1158/1538-7445.SABCS19-P1-19-28
Published: 15 February 2020
View articletitled, Abstract P1-19-28: Genomic screening reveals UBA1 as a potent and druggable target in diverse models of triple negative breast cancer
Journal Articles

Abstract 3877: IND-enabling characterization of DRD2/3 imipridone antagonist ONC206 for oncology

Varun V. Prabhu, Abed Rahman Kawakibi, Neel Madhukar, Mathew J. Garnett, Ultan McDermott, Cyril H. Benes, Lakshmi Anantharaman, Neil Charter, Sean Deacon, Alexander VanEngelenburg, Joseph B. Rucker, Benjamin J. Doranz, Jessica Rusert, Robert Wechsler-Reya, Olivier Elemento, Martin Stogniew, Wolfgang Oster, Sharon DeMorrow, R. Benjamin Free, David R. Sibley, Joshua E. Allen
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3877.
https://doi.org/10.1158/1538-7445.AM2019-3877
Published: 01 July 2019
View articletitled, Abstract 3877: IND-enabling characterization of DRD2/3 imipridone antagonist ONC206 for oncology
Journal Articles

Abstract 2749: Defining structure activity relationships for GPCR engagement and anti-cancer efficacy of imipridone small molecules

Varun V. Prabhu, Abed Rahman Kawakibi, Neel S. Madhukar, Lakshmi Anantharaman, Sean Deacon, Neil S. Charter, Mathew J. Garnett, Ultan McDermott, Cyril H. Benes, Wolfgang Oster, Olivier Elemento, Martin Stogniew, Joshua E. Allen
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2749.
https://doi.org/10.1158/1538-7445.AM2019-2749
Published: 01 July 2019
View articletitled, Abstract 2749: Defining structure activity relationships for GPCR engagement and anti-cancer efficacy of imipridone small molecules
Journal Articles

Abstract SY45-03: Capturing the therapeutic response heterogeneity at the functional level

Cyril Benes, Cyril H. Benes
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): SY45-03.
https://doi.org/10.1158/1538-7445.AM2019-SY45-03
Published: 01 July 2019
View articletitled, Abstract SY45-03: Capturing the therapeutic response heterogeneity at the functional level
Journal Articles

Abstract 3987: Predicting MCL1 inhibitor sensitivity in large cell line panels using a gene expression signature

Andreas Wernitznig, Dorothea Rudolph, Matthias Samwer, Norbert Schweifer, Francesca Trapani, Tobias Wunberg, Heribert Arnhof, Teakyu Lee, John L. Sensintaffar, Edward T. Olejniczak, Cyril H. Benes, Stephen W. Fesik, Norbert Kraut
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3987.
https://doi.org/10.1158/1538-7445.AM2019-3987
Published: 01 July 2019
View articletitled, Abstract 3987: Predicting MCL1 inhibitor sensitivity in large cell line panels using a gene expression signature
Journal Articles

A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors

Nannan Ning, Yamei Yu, Min Wu, Ruihong Zhang, Ting Zhang, Changjun Zhu, Lei Huang, Cai-Hong Yun, Cyril H. Benes, Jianming Zhang, Xianming Deng, Qiang Chen, Ruibao Ren
Journal: Cancer Research
Cancer Res (2018) 78 (20): 5949–5957.
https://doi.org/10.1158/0008-5472.CAN-18-0455
Published: 15 October 2018
View articletitled, A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors
Open the PDF for A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors in another window
Journal Articles

Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors

Cecilia Lopez Sambrooks, Marta Baro, Amanda Quijano, Azeet Narayan, Wei Cui, Patricia Greninger, Regina Egan, Abhijit Patel, Cyril H. Benes, W. Mark Saltzman, Joseph N. Contessa
Journal: Cancer Research
Cancer Res (2018) 78 (17): 5094–5106.
https://doi.org/10.1158/0008-5472.CAN-18-0505
Published: 04 September 2018
View articletitled, Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors
Open the PDF for Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors in another window
Includes: Supplementary data
Journal Articles

Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer

Luz Garcia-Alonso, Francesco Iorio, Angela Matchan, Nuno Fonseca, Patricia Jaaks, Gareth Peat, Miguel Pignatelli, Fiammetta Falcone, Cyril H. Benes, Ian Dunham, Graham Bignell, Simon S. McDade, Mathew J. Garnett, Julio Saez-Rodriguez
Journal: Cancer Research
Series: Author Choice
Cancer Res (2018) 78 (3): 769–780.
https://doi.org/10.1158/0008-5472.CAN-17-1679
Published: 31 January 2018
View articletitled, Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer
Open the PDF for Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer in another window
Includes: Supplementary data
Journal Articles

APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition

Rémi Buisson, Michael S. Lawrence, Cyril H. Benes, Lee Zou
Journal: Cancer Research
Cancer Res (2017) 77 (17): 4567–4578.
https://doi.org/10.1158/0008-5472.CAN-16-3389
Published: 31 August 2017
View articletitled, APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition
Open the PDF for APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition in another window
Includes: Supplementary data
Journal Articles

Abstract 1007: SHP2 inhibition restores sensitivity to ALK inhibition in resistant ALK-rearranged non-small cell lung cancer (NSCLC)

Leila Dardaei, Hui Qin Wang, Paul Fordjour, Manrose Singh, Grainne Kerr, Satoshi Yoda, Jinsheng Liang, Yichen Cao, Yan Chen, Justin F. Gainor, Luc Friboulet, Ibiayi Dagogo-Jack, David T. Myers, Emma Labrot, David Ruddy, Melissa Parks, Dana Lee, Richard H. DiCecca, Susan Moody, Huaixiang Hao, Morvarid Mohseni, Matthew LaMarche, Juliet Williams, Keith Hoffmaster, Giordano Caponigro, Cyril H. Benes, Alice T. Shaw, Aaron N. Hata, Fang Li, Jeffrey A. Engelman
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1007.
https://doi.org/10.1158/1538-7445.AM2017-1007
Published: 01 July 2017
View articletitled, Abstract 1007: SHP2 inhibition restores sensitivity to ALK inhibition in resistant ALK-rearranged non-small cell lung cancer (NSCLC)
Journal Articles

Abstract 1118: Synthetic lethality of CDK12 inhibition in tumors with EWS/FLI rearrangements

Amanda L. Balboni, Bjorn Stolte, Amy Saur Conway, Gabriela Alexe, Emily Jue Wang, Nicholas Kwiatkowski, Tinghu Zhang, Brian J. Abraham, Peter Kalev, Dipanjan Chowdhury, Cyril H. Benes, Richard A. Young, Nathanael S. Gray, Kimberly Stegmaier
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1118.
https://doi.org/10.1158/1538-7445.AM2017-1118
Published: 01 July 2017
View articletitled, Abstract 1118: Synthetic lethality of CDK12 inhibition in tumors with EWS/FLI rearrangements
Journal Articles

Abstract 4756: A SPP1-EGFR pathway links stem-like properties of KRAS-mutated lung cancer to radiation resistance

Meng Wang, Jing Han, Lynnette Marcar, Josh Black, Qi Liu, Xiangyong Li, Kshithija Nagulapalli, Lecia V. Sequist, Raymond H. Mak, Cyril H. Benes, Theodore S. Hong, Kristin Gurtner, Mechthild Krause, Michael Baumann, Jing X. Kang, Johnathan R. Whetstine, Henning Willers
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4756.
https://doi.org/10.1158/1538-7445.AM2017-4756
Published: 01 July 2017
View articletitled, Abstract 4756: A SPP1-EGFR pathway links stem-like properties of KRAS-mutated lung cancer to radiation resistance
Journal Articles

Abstract 543: Harnessing synthetic lethality to predict clinical outcomes of cancer treatment

Joo Sang Lee, Avinash Das, Livnat Jerby-Arnon, Seung Gu Park, Matthew Davidson, Dikla Atias, Arnaud Amzallag, Chani Stossel, Ella Buzhor, Welles Robinson, Kuoyuan Cheng, Joshua J. Waterfall, Paul S. Meltzer, Sridhar Hannenhalli, Cyril H. Benes, Talia Golan, Emma Shanks, Eytan Ruppin
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 543.
https://doi.org/10.1158/1538-7445.AM2017-543
Published: 01 July 2017
View articletitled, Abstract 543: Harnessing synthetic lethality to predict clinical outcomes of cancer treatment
Journal Articles

Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin–EGFR Pathway

Meng Wang, Jing Han, Lynnette Marcar, Josh Black, Qi Liu, Xiangyong Li, Kshithija Nagulapalli, Lecia V. Sequist, Raymond H. Mak, Cyril H. Benes, Theodore S. Hong, Kristin Gurtner, Mechthild Krause, Michael Baumann, Jing X. Kang, Johnathan R. Whetstine, Henning Willers
Journal: Cancer Research
Cancer Res (2017) 77 (8): 2018–2028.
https://doi.org/10.1158/0008-5472.CAN-16-0808
Published: 13 April 2017
View articletitled, Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin–EGFR Pathway
Open the PDF for Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin–EGFR Pathway in another window
Includes: Supplementary data
Journal Articles

Abstract 349: Structure-activity relationships and mechanistic analysis of analogues of the clinical-stage anti-cancer small molecule ONC201

Jessica Wagner, Gary Olson, Nallaganchu Rao Bhaskara, Richard S. Pottorf, Garnett J. Mathew, Cyril H. Benes, Rohinton Tarapore, Martin Stogniew, Lee Schalop, Wolfgang Oster, Josh E. Allen, Wafik S. El-Deiry
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 349.
https://doi.org/10.1158/1538-7445.AM2016-349
Published: 15 July 2016
View articletitled, Abstract 349: Structure-activity relationships and mechanistic analysis of analogues of the clinical-stage anti-cancer small molecule ONC201
Journal Articles

Abstract LB-209: D2-like dopamine receptor antagonism by ONC201 identified by confluence of computational, receptor binding, and clinical studies

Neel S. Madhukar, Olivier Elemento, Cyril H. Benes, Mathew J. Garnett, Mark Stein, Joseph R. Bertino, Howard L. Kaufman, Isabel Arrillaga-Romany, Tracy T. Batchelor, Lee Schalop, Wolfgang Oster, Martin Stogniew, Michael Andreeff, Wafik S. El-Deiry, Joshua E. Allen
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): LB-209.
https://doi.org/10.1158/1538-7445.AM2016-LB-209
Published: 15 July 2016
View articletitled, Abstract LB-209: D2-like dopamine receptor antagonism by ONC201 identified by confluence of computational, receptor binding, and clinical studies